New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export MRK’s income statement to Excel — free account
Merck & Co., Inc.
MRKHealthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −12.1%
- Free cash flow
- −19.3%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
134.98
2.24
+1.69%
Follow MRK
Alert me
What it owns vs. what it owes Q3 FY2026, Sep 30, 2026
It owes $40.0B more in debt than it holds in cash and short-term investments. Debt has risen from $46.8B to $49.7B since Q4 FY25. Shareholders’ equity is 33.9% of the balance sheet. What is a balance sheet?
Owns
$93.8BLong-term assets
$29.3BOther short-term assets
$9.7BCash & short-term investments
Funded by
$44.9BShareholders’ equity
$38.1BOther liabilities
$49.7BDebt
Debt is 37.4% of the total; shareholders’ equity 33.9%.
Net debt rose from 24% of assets to 30% since Q4 FY25.
Net debt ÷ assets (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Total assets | $136.9B | $128.7B | $129.8B | $132.8B |
| Net debt (debt less cash) | $32.2B | $41.0B | $43.9B | $40.0B |
| Net debt ÷ assets (right axis) | 23.5% | 31.8% | 33.9% | 30.2% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
14,565.00 | 5,702.00 | 7,141.00 | 9,650.00 |
Receivables |
11,775.00 | 12,210.00 | 12,564.00 | 12,744.00 | |
Inventory |
6,658.00 | 6,479.00 | 6,207.00 | 6,164.00 | |
Other current assets |
10,518.00 | 10,624.00 | 10,767.00 | 10,383.00 | |
Total current assets |
43,516.00 | 35,015.00 | 36,679.00 | 38,941.00 | |
Property, Plant, Equpment (Net) |
25,316.00 | 25,433.00 | 25,737.00 | 25,904.00 | |
Long-Term Investments |
956.00 | 1,105.00 | 1,222.00 | 1,603.00 | |
Goodwill and Intangible Assets (Total) |
48,260.00 | 47,326.00 | 46,560.00 | 46,427.00 | |
Long-term assets (Other) |
18,818.00 | 19,806.00 | 19,604.00 | 19,898.00 | |
Total non-current assets |
93,350.00 | 93,670.00 | 93,123.00 | 93,832.00 | |
Total Assets |
136,866.00 | 128,685.00 | 129,802.00 | 132,773.00 | |
Notes Payable |
2,589.00 | 2,444.00 | 2,825.00 | 4,088.00 | |
Accounts Payable |
4,404.00 | 3,863.00 | 3,827.00 | 5,031.00 | |
Dividends Payable |
2,140.00 | 2,143.00 | 2,130.00 | 2,134.00 | |
Accrued Expenses |
14,468.00 | 14,549.00 | 14,725.00 | 13,239.00 | |
Current Part of Taxes to Pay |
4,726.00 | 3,946.00 | 4,224.00 | 4,309.00 | |
Total current liabilities |
28,327.00 | 26,945.00 | 27,731.00 | 28,801.00 | |
Long Term Debt (Total) |
46,750.00 | 46,673.00 | 51,081.00 | 49,689.00 | |
Long Term Tax Liability (Deferred) |
1,439.00 | 1,494.00 | 1,433.00 | 1,460.00 | |
Non-current Liabilities (Other) |
7,688.00 | 7,642.00 | 7,573.00 | 7,877.00 | |
Total non-current liabilities |
55,877.00 | 55,809.00 | 60,087.00 | 59,026.00 | |
Total liabilities |
84,204.00 | 82,754.00 | 87,818.00 | 87,827.00 | |
Additional Paid In Capital |
45,029.00 | 45,176.00 | 44,950.00 | 45,362.00 | |
Common Stock (Net) |
1,788.00 | 1,788.00 | 1,788.00 | 1,788.00 | |
Retained Earnings |
73,075.00 | 66,721.00 | 63,269.00 | 66,223.00 | |
Treasury Stock |
62,999.00 | 63,747.00 | 64,132.00 | 64,592.00 | |
Common Equity (Total) |
52,662.00 | 45,931.00 | 41,984.00 | 44,946.00 | |
Shareholders Equity (Total) |
52,662.00 | 45,931.00 | 41,984.00 | 44,946.00 | |
Shareholders Equity and Liabilities (Total) |
136,866.00 | 128,685.00 | 129,802.00 | 132,773.00 | |
Shares (Common) |
2,474.63 | 2,469.69 | 2,468.64 | 2,466.77 | |
Shareholders Equity (Tangible) |
4,402.00 | (1,395.00) | (4,576.00) | (1,481.00) | |
Net Debt |
32,185.00 | 40,971.00 | 43,940.00 | 40,039.00 | |
Total Debt |
46,750.00 | 46,673.00 | 51,081.00 | 49,689.00 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026